Nasdaq: GTBP

Investor Relations

Investor Relations

GT Biopharma Announces First Patient Dosed in Phase 1 Trial of GTB-3650, Second-Generation TriKE for the Treatment of Hematologic Malignancies

Jan 27, 2025

Read Press Release

2024

Year End Results

Dec 31, 2024

PDF HTML

ZIP XLS HTML

XBRL

Nasdaq:

GTBP

Price

Change

MKT Cap

Volume

52 week Low/High

Day Low/High